07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Cebranopadol: Phase III data

The double-blind, international Phase III CORAL trial in 125 patients with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol met the primary endpoint of non-inferiority to twice-daily oral...
07:00 , Sep 30, 2016 |  BC Extra  |  Clinical News

Gruenenthal's cebranopadol meets Phase III pain endpoint

Gruenenthal Group (Aachen, Germany) said once-daily cebranopadol ( GRT6005) met the primary endpoint of a Phase III study to treat cancer-related pain. The company said cebranopadol was non-inferior, as well as superior, to twice-daily prolonged-release...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Gruenenthal, Depomed deal

Gruenenthal will grant Depomed exclusive rights to develop and commercialize cebranopadol in the U.S. and Canada. The small molecule opioid analgesic is in Phase II testing for moderate to severe pain. Gruenenthal will receive a...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Gruenenthal, Forest Laboratories deal

Gruenenthal and Actavis plc (NYSE:ACT, Dublin, Ireland) terminated a 2010 deal granting Actavis’ subsidiary, Forest Laboratories, exclusive rights to co-develop and commercialize cebranopadol ( GRT6005) in the U.S. and Canada to treat chronic pain....
08:00 , Jan 24, 2011 |  BioCentury  |  Finance

Less VC, more SBIR

Altor BioScience Corp. and its investors have structured a financing strategy that keeps the company eligible for Small Business Innovation Research grants, thus reducing dilutive equity funding. Investors hope last week's $10.3 million series D...
08:00 , Dec 13, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Orexigen Therapeutics Inc. (NASDAQ:OREX) gained $3.60 (75%) to $8.41 last week after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-7 that the benefit-risk profile of Contrave supports approval as a long-term treatment for...
01:51 , Dec 7, 2010 |  BC Extra  |  Company News

Forest, Gruenenthal unveil pain deal

Gruenenthal Group (Aachen, Germany) granted Forest Laboratories Inc. (NYSE:FRX) exclusive rights in the U.S. and Canada to co-develop and commercialize two candidates for pain. GRT6005 and follow-on compound GRT6006 are agonists of opioid receptor (OPR)...